Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure that innovative technologies that improve the identification of heart murmurs, particularly in primary care and community pharmacies, are supported by clear commissioning guidance and sustainable reimbursement pathways to incentivise earlier diagnosis.

The Department encourages innovation in the health sector that helps to support the three big shifts in healthcare: moving care from hospitals to communities, transitioning from analogue to digital, and focusing on prevention over treatment, which are set out as part of the 10-Year Health Plan. As set out in the plan, we will publish a new Cardiovascular Disease Modern Service Framework (CVD MSF) in spring 2026.

The framework will support consistent, high quality and equitable care and identify current and emerging innovations across the CVD pathway. We will consider the role of Government in supporting areas where we need to go further.

The 10-Year Health Plan sets out that integrated care boards (ICBs) will be strategic commissioners of local health services, ensuring that the money available to each local care system is put to the best possible use: to improve their population’s health, reduce health inequalities and improve access to consistently high-quality services. They are expected to draw on a deep understanding of population need and will need to shape commissioning plans through deep engagement with patients and the public.

To support this, on 4 November 2025, NHS England published more detailed expectations of ICBs in the Strategic Commissioning Framework. This sets out how to make best use of the whole National Health Service budget they deploy for the population: ensuring that care models match the real needs of the population, taking action to ensure individuals access the appropriate care, rigorously pursuing improved outcomes and value for money for their public.

In terms of service innovation, NHS England currently commissions the community pharmacy NHS Hypertension Case Finding service that focusses on the detection of people at risk of cardiovascular disease from high blood pressure and where it is captured the measurement of pulse rate. The data is shared with the patient’s general practitioner who will then use this information to inform any diagnosis and clinical intervention as appropriate.

Pharmacies are central to plans to create a Neighbourhood Health Service. ICB strategic commissioning will in future assess needs of local populations, prioritise commissioning based on evidence, strengthen their understanding of the role of technology and data in how and what they commission, including digital health technology and artificial intelligence, and develop models of multi neighbourhood providers.

In relation to medical devices outside of hospital, if a newly developed medical device is deemed appropriate for prescribing in primary or community care, the manufacturer has the option to apply for inclusion in the drug tariff. Once listed, the company can formalise a supply route via community pharmacies. This arrangement ensures that the device can be prescribed and dispensed to patients, with the company receiving reimbursement for the supply of their product through the established system.